Text Size
22 studies found for:    GS-7977 | Gilead [Lead]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting GS-7977 and Ribavirin in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection
Condition: Hepatitis C
Interventions: Drug: GS-7977 + RBV;   Drug: GS-7977 placebo + RBV placebo
2 Active, not recruiting GS-7977 + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Condition: Chronic Hepatitis C
Intervention: Drug: GS-7977 in combination with ribavirin
3 Active, not recruiting GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection
Condition: Chronic Hepatitis C
Intervention: Drug: GS 7977 in combination with PEG and RBV
4 Active, not recruiting GS-7977 + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 HCV Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: GS-7977 in combination with ribavirin;   Drug: GS 7977 placebo in combination with RBV placebo
5 Active, not recruiting Part A: Drug Interaction Study of GS-7977 and Antiretroviral Therapy(ART) Combinations in Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-infected Patients. Part B: Phase 2, Open-Label Study to Investigate Efficacy and Safety of GS-7977 for 12 Weeks in HIV/HCV Co-infected Patients.
Conditions: Hepatitis C;   HIV
Interventions: Drug: GS-7977;   Drug: Efavirenz (EFV);   Drug: Tenofovir (TDF);   Drug: Emtricitabine (FTC);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Zidovudine (ZDV);   Drug: Lamivudine (3TC);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Raltegravir (RAL);   Drug: Ribavirin (RBV);   Drug: Peginterferon Alfa 2a (PEG)
6 Recruiting Open-Label Study of GS-7977+ Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies
Condition: Chronic Hepatitis C
Interventions: Drug: GS-7977 in combination with ribavirin;   Drug: GS-7977 400mg QD+ RBV BID+ PEG
7 Active, not recruiting A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects
Conditions: Hepatitis C,;   Human Immunodeficiency Virus
Intervention: Drug: GS-7977 + Ribavirin
8 Recruiting GS-7977 and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
Conditions: Hepatitis C;   Cirrhosis;   Portal Hypertension;   With or Without Liver Decompensation
Interventions: Drug: GS-7977;   Drug: Ribavirin
9 Active, not recruiting Study to Investigate GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Conditions: Recurrent Chronic Hepatitis C Virus;   Post Liver Transplant
Interventions: Drug: GS-7977;   Drug: Ribavirin
10 Active, not recruiting An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Conditions: Hepatitis C;   Hepatocellular Carcinoma
Intervention: Drug: GS-7977+RBV
11 Recruiting Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3
Condition: Hepatitis C
Intervention: Drug: SOF in combination with PEG and RBV
12 Recruiting Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, or 3 HCV Infection
Condition: Chronic Hepatitis C
Interventions: Drug: SOF/LDV FDC;   Drug: SOF;   Drug: RBV;   Drug: PEG;   Drug: GS-9669
13 Recruiting Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3
Condition: Chronic Hepatitis C Infection
Interventions: Drug: PSI-7977;   Drug: Ribavirin;   Drug: Pegylated-Interferon;   Drug: GS-5885;   Drug: GS-9669;   Drug: Sofosbuvir/GS-5885 400/90 mg
14 Recruiting Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin
15 Active, not recruiting Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/-Ribavirin in HCV Genotype 1 Subjects
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin
16 Available Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C
Condition: Post-transplant Recurrent Hepatitis C
Intervention: Drug: Sofosbuvir + RIbavirin +/- Pegylated Interferon
17 Recruiting Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/Ledipasvir 400/90 mg;   Drug: Ribavirin
18 Active, not recruiting Safety and Efficacy of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for the Treatment of HCV
Condition: Chronic Hepatitis C Virus
Interventions: Drug: Sofosbuvir/GS-5885 400/90 mg;   Drug: Ribavirin
19 Completed Dose-Ranging Study of PSI-7977 in Combination With SOC in Treatment Naïve GT 1 HCV Patients
Condition: Hepatitis C
Interventions: Drug: PSI-7977 100 mg;   Drug: PSI-7977 200 mg;   Drug: PSI-7977 400 mg;   Drug: Placebo;   Drug: Pegylated Interferon (PEG);   Drug: Ribavirin (RBV)
20 Completed Safety Study to Investigate PSI-7977 in Combination With SOC in Treatment-Naïve HCV Patients With Chronic Hepatitis C Virus(HCV) Infection
Condition: Hepatitis C Virus
Interventions: Drug: PSI-7977 200 mg;   Drug: PSI-7977 400 mg;   Drug: Placebo;   Drug: Pegylated Interferon (PEG);   Drug: Ribavirin (RBV)
To Top

Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results
† Indicates status has not been verified in more than two years